Cryoport IntegriCell cryopreservation services win selection by Verismo Therapeutics for clinical KIR-CAR T trials
PUBT · 15h ago
Share
Listen to the news
- Cryoport announced Verismo Therapeutics selected its IntegriCell cryopreservation services to support two clinical KIR-CAR T cell therapy programs.
- Scope includes process development, technology transfer, clinical cryopreservation services for SynKIR-110, SynKIR-310, both in Phase 1 trials.
- Service delivery to run through IntegriCell centers in Houston, Texas, or Liège, Belgium, tied into Cryoport’s temperature-controlled supply chain platform.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cryoport Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA91964) on June 25, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved